GH Research (GHRS) Stock Overview
Together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GHRS Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
GH Research PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.79 |
| 52 Week High | US$20.50 |
| 52 Week Low | US$6.85 |
| Beta | 0.97 |
| 1 Month Change | -13.32% |
| 3 Month Change | -11.46% |
| 1 Year Change | 79.56% |
| 3 Year Change | 31.53% |
| 5 Year Change | n/a |
| Change since IPO | -33.58% |
Recent News & Updates
We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business Growth
Dec 11
We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Aug 27Recent updates
We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business Growth
Dec 11We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Aug 27We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
May 10We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Jan 31We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
Oct 11We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
Jun 21GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Mar 01GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Jul 30We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash Wisely
Mar 13Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In Growth
Nov 28GH Research GAAP EPS of $0.006
Aug 23We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Aug 15GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Apr 29We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn Rate
Jan 13GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth Plans
Sep 30GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry
Aug 15Shareholder Returns
| GHRS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.4% | 1.4% | 1.3% |
| 1Y | 79.6% | 26.0% | 15.8% |
Return vs Industry: GHRS exceeded the US Pharmaceuticals industry which returned 26% over the past year.
Return vs Market: GHRS exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| GHRS volatility | |
|---|---|
| GHRS Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GHRS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GHRS's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 50 | Villy Valcheva | www.ghres.com |
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The company also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders.
GH Research PLC Fundamentals Summary
| GHRS fundamental statistics | |
|---|---|
| Market cap | US$793.05m |
| Earnings (TTM) | -US$42.92m |
| Revenue (TTM) | n/a |
Is GHRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GHRS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.92m |
| Earnings | -US$42.92m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GHRS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 22:53 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GH Research PLC is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Cantor Fitzgerald & Co. |